⌘K

16:29:26·18d

SECFilingvia Quantisnow

SEC Form S-8 filed by Corcept Therapeutics Incorporated

ByQuantisnow·Wall Street's wire, on your screen.

CORT· Corcept Therapeutics Incorporated

Health Care

Original source

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Related

Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
Chief Development Officer Guyer William exercised 20,000 shares at a strike of $21.65 and sold $1,412,000 worth of shares (20,000 units at $70.60) as part of a pre-agreed trading plan (SEC Form 4)
Officer Lyon Joseph Douglas was granted 1,074 shares and covered exercise/tax liability with 269 shares, increasing direct ownership by 13% to 7,035 units (SEC Form 4) (tax liability)
Chief Development Officer Guyer William was granted 1,754 shares, increasing direct ownership by 79% to 3,985 units (SEC Form 4)
Officer Maduck Sean exercised 25,000 shares at a strike of $8.27, sold $1,755,183 worth of shares (25,000 units at $70.21) as part of a pre-agreed trading plan, was granted 1,230 shares and covered exercise/tax liability with 452 shares, increasing direct ownership by 9% to 9,755 units (SEC Form 4) (for withholding tax)